---
schema_version: "secwatch.filing_event.v1"
accession: "0000914475-24-000210"
form_type: "8-K"
ticker: "NBIX"
cik: "0000914475"
company_name: "NEUROCRINE BIOSCIENCES INC"
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:48:36.042631+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Neurocrine Q3 INGREZZA sales $613M (+26% YoY); raises FY2024 guidance; $300M buyback

## Summary
- INGREZZA net product sales $613M in Q3 2024, up 26% YoY; raised 2024 sales guidance to $2.30-$2.32B.
- Total revenues $622.1M (+25% YoY); GAAP EPS $1.24 vs $0.82; Non-GAAP EPS $1.81 vs $1.54.
- Board authorized $300M share repurchase plan; intends to enter accelerated share repurchase.
- New CEO Kyle W. Gano appointed effective Oct 11, 2024; Phase 2 data for NBI-1117568 triggered $35M milestone.
- Terminated licenses for luvadaxistat (CIAS) and NBI-827104; terminations expected in 2025.

## SEC filing metadata
- accession: 0000914475-24-000210
- form_type: 8-K
- ticker: NBIX
- cik: 0000914475
- company_name: NEUROCRINE BIOSCIENCES INC
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/914475/000091447524000210/0000914475-24-000210-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/914475/000091447524000210/nbix-20241030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000914475-24-000210
- JSON: https://secwatch.observer/filing/0000914475-24-000210.json
- Plain text: https://secwatch.observer/filing/0000914475-24-000210.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.